Carcinoma News and Research

RSS

Carcinoma is cancer that begins in the skin or in tissues that line or cover internal organs.

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Genentech, Inc., a member of the Roche Group, today announced that information submitted by the company to the U.S. Food and Drug Administration (FDA) during the review of the supplemental Biologics License Applications (sBLAs) for Avastin (bevacizumab) for previously untreated (first-line) advanced HER2-negative breast cancer has been deemed a major amendment.

18 Sep 2010

Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000

Spirogen Limited and Celtic Therapeutics Holdings LP announced today the commencement of a Phase II clinical trial of SG2000 in ovarian cancer. The trial is being sponsored by the National Cancer Institute of the USA, and is now actively recruiting patients for treatment.

16 Sep 2010

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

Kowa Company, Ltd. announced today that the results of a Phase II/III trial showed that high dose peretinoin (NIK-333) given daily for up to 96 weeks reduced the recurrence of hepatocellular carcinoma (HCC) after surgical resection or ablation in hepatitis C virus (HCV) positive patients when compared to placebo.

13 Sep 2010

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

CEL-SCI Corporation announced today it has received approval from the North Mississippi Health Services Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.

13 Sep 2010

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that it was expanding its Phase 2 clinical trial of STA-9090 in patients with Stage IIIB and Stage IV non-small cell lung cancer (NSCLC) from up to 69 patients to up to 146 patients based on encouraging activity observed in the first stage of the two stage clinical trial.

13 Sep 2010

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Jennerex, Inc., a clinical-stage biotherapeutics company focused on the development of first-in-class, targeted oncolytic products for cancer, today reported positive interim data from a pilot trial using JX-594 followed by sorafenib (Nexavar®) to treat liver cancer patients. The data were presented today at the Fourth Annual International Liver Cancer Association Conference in Montreal, Canada.

13 Sep 2010

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Among Asian-Americans living in California, Laotian/Hmong-Americans have the lowest survival rates for the most common type of liver cancer, a new study by researchers with the UC Davis School of Medicine has found.

10 Sep 2010

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Allos Therapeutics, Inc. today announced that results from the Phase 2b investigational trial of FOLOTYN (pralatrexate injection) versus erlotinib in patients with Stage IIIB/IV (advanced) non-small cell lung cancer (NSCLC) will be presented at the 35th European Society of Medical Oncology (ESMO) Congress

10 Sep 2010

Quercetin and ferulic acid antioxidants aggravate kidney cancer in severely diabetic rats

Scientists are calling for more research on the possibility that some supposedly healthful plant-based antioxidants - including those renowned for their apparent ability to prevent cancer - may actually aggravate or even cause cancer in some individuals. Their recommendation follows a study in which two such antioxidants - quercetin and ferulic acid - appeared to aggravate kidney cancer in severely diabetic laboratory rats. The study appears in ACS' bi-weekly Journal of Agricultural and Food Chemistry.

9 Sep 2010

Two genes linked to ovarian clear cell carcinoma

Scientists at the Johns Hopkins Kimmel Cancer Center have identified two genes whose mutations appear to be linked to ovarian clear cell carcinoma, one of the most aggressive forms of ovarian cancer. Clear cell carcinoma is generally resistant to standard therapy.

9 Sep 2010

BC gynecologists initiate campaign to reduce ovarian cancer mortality

Gynecologic oncologists with the Ovarian Cancer Research Program at Vancouver General Hospital (VGH) and the BC Cancer Agency have begun an important campaign that will reduce deaths from ovarian cancer.

9 Sep 2010

ARID1A gene links ovarian cancer to endometriosis

Researchers with the Ovarian Cancer Research Program of BC (OvCaRe) reveal a major new cancer gene-ARID1A. Mutations are frequent in this gene and link two types of ovarian cancer to endometriosis.

9 Sep 2010

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Perrigo Company announced it received FDA approval from the U.S. Food and Drug Administration to manufacture and market Imiquimod Cream, 5%. Perrigo will vertically integrate this product with their own API.

8 Sep 2010

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Jennerex, Inc., a private clinical-stage biotherapeutics company focused on the development and commercialization of first-in-class targeted oncolytic products for cancer, and Transgene Euronext, a bio-pharmaceutical company specialized in the development of immunotherapeutic products, today announced that they have entered into an exclusive partnership to develop and commercialize JX-594 for the treatment of solid tumors in Europe, the Commonwealth of Independent States (CIS) and the Middle East.

8 Sep 2010

Researchers develop new RNA molecule approach to kill cancer cells

Researchers at the California Institute of Technology (Caltech) have engineered a fundamentally new approach to killing cancer cells. The process developed by Niles Pierce, associate professor of applied and computational mathematics and bioengineering at Caltech, and his colleagues uses small RNA molecules that can be programmed to attack only specific cancer cells then, by changing shape, those molecules cause the cancer cells to self destruct.

8 Sep 2010

Tikcro reports $3.2 million net loss for second-quarter 2010

Tikcro Technologies Ltd. today reported results for the second quarter and six months ended June 30, 2010.

7 Sep 2010

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

The decision regarding treatment following breast-conserving surgery for patients diagnosed with ductal carcinoma in-situ (DCIS) has long been an area of discussion and confusion for patients and physicians alike. While the mortality rates for DCIS remain low, the risk of local recurrence in the breast is high. Standard treatments following surgery include radiation therapy and hormone treatment.

4 Sep 2010

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Celsion Corporation, a biotechnology drug development company, announced today that it has been awarded a competitive Phase I Small Business Innovation and Research (SBIR) grant from the National Institutes of Health (NIH), to support the proposal, "New Thermal Sensitive Carboplatin Liposomes for Cancer".

3 Sep 2010

Abbott RealTime HBV assay receives marketing approval from FDA

Abbott announced today it has received approval from the U.S. Food and Drug Administration to market the Abbott RealTime HBV assay for measuring viral load or the amount of hepatitis B virus in a patient's blood. It is the first and only approved test capable of automating HBV viral load testing from sample extraction to final results.

2 Sep 2010

Consuming variety of fruits, vegetables may decrease squamous cell lung cancer risk: Study

Adding a variety of vegetables to one's diet may help decrease the chance of getting lung cancer, and adding a variety of fruits and vegetables may decrease the risk of squamous cell lung cancer, especially among smokers.

2 Sep 2010

Carcinoma News and Research

Further Reading

FDA decides to review information on Avastin for advanced HER2-negative breast cancer

Spirogen, Celtic Therapeutics announces initiation of Phase II ovarian cancer trial with SG2000

High dose peretinoin reduces recurrence of HCC after surgical resection or ablation in HCV positive patients

North Mississippi IRB approves CEL-SCI's Multikine Phase III clinical trial for head and neck cancer

Synta expands STA-9090 Phase 2 clinical trial in NSCLC

Jennerex reports positive interim data from trial of JX-594 and sorafenib for liver cancer

Study finds Laotian/Hmong-Americans have low survival rates for liver cancer

Allos Therapeutics to present FOLOTYN trial results at ESMO Congress

Quercetin and ferulic acid antioxidants aggravate kidney cancer in severely diabetic rats

Two genes linked to ovarian clear cell carcinoma

BC gynecologists initiate campaign to reduce ovarian cancer mortality

ARID1A gene links ovarian cancer to endometriosis

Perrigo receives FDA approval to manufacture, market Imiquimod Cream, 5%

Jennerex, Transgene enter partnership to develop JX-594 product for tumor treatment

Researchers develop new RNA molecule approach to kill cancer cells

Tikcro reports $3.2 million net loss for second-quarter 2010

MSKCC develops new prediction tool to calculate risk for DCIS recurrence after breast-conserving surgery

Celsion receives SBIR grant to develop heat sensitive liposomal technology for cancer treatment

Abbott RealTime HBV assay receives marketing approval from FDA

Consuming variety of fruits, vegetables may decrease squamous cell lung cancer risk: Study

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News